[ClickPress, Tue Jul 02 2019] This report on the global
Hereditary Angioedema Market analyzes the current and future prospects of the market.
The "Market Spotlight:
Hereditary Angioedema (HAE)" report has been added to ResearchAndMarkets.com's offering.
Questionnaire for patients with
hereditary angioedemaThey were aged between 7 and 70 years (mean: 34.5 y; median: 32 y), and 36/51 (70.6%) had a family history of suspected or confirmed
hereditary angioedema. Symptoms were reported in 46/51 (90.2%), and 5/51 (9.8%) remained asymptomatic.
The drug BCX7353, developed by BioCryst Pharmaceuticals, is taken orally and works by inhibiting plasma kallikrein, an enzyme overexpressed in
hereditary angioedema, a rare genetic disease that causes severe tissue swelling.
The product is claimed to be the only monoclonal antibody that provides targeted inhibition of plasma kallikrein, an enzyme which is chronically uncontrolled in people with
hereditary angioedema, to help prevent attacks.
Emel Aygören-Pürsün, M.D., from University Hospital Frankfurt in Germany, and colleagues randomized 77 patients with type I or II
hereditary angioedema with a history of at least two angioedema attacks per month to BCX7353 (at four doses: 62.5, 125, 250, and 350 mg) or placebo.
The histologic findings are prominent minor salivary glands and a mixed inflammatory cell infiltrate.5 The differential diagnosis includes
hereditary angioedema, early dermatochalasis, acquired cutis laxa and variants of granulomatous cheilitis.
Evaluation of the case reveals several failings in the patient's treatment; although the emergency physician was made aware of the nature of the edema,
hereditary angioedema was not recognized by the treating physician.
A 32-year-old female was diagnosed with
hereditary angioedema type l (C1-INH-HAE) in 2004.
Keywords: C1 esterase inhibitor,
hereditary angioedema, screening, questionnaires, C4